Report #2828665

Received Feb 27, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: Feb 21, 2025
Onset: Feb 1, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (2)

Injection site erythemaInjection site pain

Symptom narrative

Injection site pain and redness; Injection site pain and redness; This non-serious case was reported by a nurse via sales rep and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 21-FEB-2025, the patient received the 2nd dose of Shingrix (unknown arm). In FEB-2025, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: Injection site pain and redness) and injection site erythema (Verbatim: Injection site pain and redness). The outcome of the injection site pain and injection site erythema were resolved. The reporter considered the injection site pain and injection site erythema to be related to Shingrix. The company considered the injection site pain and injection site erythema to be related to Shingrix. Additional Information: GSK Receipt Date: 25-FEB-2025 The nurse reported that a patient received Shingrix vaccine after that experienced injection site pain and redness.